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ABSTRACT

Heterologous polypeptides are produced in the milk of
transgenic non-human mammals by the expression of a
Stably integrated DNA sequence containing the long whey
acidic protein promoter operably linked to a DNA sequence
encoding a heterologous polypeptide and a signal Sequence.
The transgenic non-human mammals of the present inven
tion are produced by introducing this DNA sequence Such
that the DNA sequence is stably integrated into the DNA of
germ line cells of the mature mammal and inherited in
normal Mendelian fashion. A representative heterologous
polypeptide is protein C.
20 Claims, 8 Drawing Sheets
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EXPRESSION OF A HETEROLOGOUS
POLYPEPTIDE IN MAMMARY TISSUE OF
TRANSGENIC NON-HUMAN MAMMALS
USING ALONG WHEY ACIDIC PROTEIN
PROMOTER

TABLE 1.
PARTIAL ESTIMATE OF U.S. CLINICAL REOUIREMENTS
FOR PROTEIN CAND ACTIVATED PROTEIN C

Estimated

This application is a continuation-in-part of U.S. Ser. No.
07/638,995, filed Jan. 11, 1992, which is herein incorporated
by reference.
The present invention relates to the production of natural
and modified forms of the human coagulation factor protein
C. In particular, the invention relates to a transgenic animal
containing, stably incorporated in its genomic DNA, an
exogenous gene which is expressed specifically in mammary
tissue, Such that protein C is Secreted into milk produced by
the animal. In particular, the invention relates to the pro
duction of natural and modified forms of protein C in the
milk of a transgenic non-human mammal using a DNA
molecule that comprises a long whey acidic protein pro
moter fragment and genomic DNA encoding human protein
C. The long whey acidic protein promoter fragment also can
be used to express high levels of other genes in mammary
cells of transgenic non-human mammals.

15

120,000
800,000
200,000

0.6-6.0
8-8O
2-20

Homozygous Deficient

3

100 x 365*

Heterozygous Deficient

50

Per Year

1,000

Req. (Kg)

O.10

O.OS
10.8-106.2

* 100 individuals in U.S. x 365 treatment/year
**Refers to the use of APC, following thrombolytic therapy, to prevent the
reformation of blood clots.

The gene for human protein C has been cloned and
Sequenced, as has bovine protein C gene. See Forster et al.,

Proc. Nat'l Acad. Sci. USA 82: 4673 (1985); U.S. Pat. No.

25

4,775,624. It is synthesized as an inactive precursor that
undergoes Several proteolytic events during the processes of
Secretion and activation. First, a signal Sequence as pro
teolytically removed upon Secretion. A Second proteolytic
event removes the dipeptide lyS156 arg157, producing the
inactive Zymogen, a two chain disulfide bridged protein,
consisting of a light chain of 155 amino acids and a heavy
chain of 262 amino acids. The Zymogen is activated by a
final proteolytic event that removes residues 158-169, yield
ing active protein C, a Serine protease with potent antico
agulant activity. Beckmann et al., Nucleic Acids Res. 13:

5233 (1985).
In addition to proteolytic processing, human protein C
35

activated protein C (APC) by limited thrombin proteolysis in

undergoes Several post-translation modifications. Perhaps
most Salient among these modifications is the
Y-carboxylation of the first nine glutamic acid residues in
protein C, by a vitamin K dependent enzyme. DiScipio &

Davie, Biochemistry 18: 899 (1979). Gamma-carboxylation

is required for anticoagulant activity, and is associated with
40

(Brown, Grune and Stratton, Inc. 1983).
45

Caf'-dependent membrane binding. The anticoagulant

activity of protein C varies directly with the extent of
Y-carboxylation, and the highest levels of activity are
achieved only when Y-carboxylation of the sixth and seventh
glutamic acid residues is effected. Zhang & Castellino,

Biochemistry 29: 10829 (1990).

Protein C is also post-translationally modified by
B-hydroxylation of aspartic acid 71. Drakenberg et al., Proc.

contains the nine Y-carboxyglutamic acid (Gla) residues

required for calcium-dependent membrane binding and
functional activation. Another post-translational modifica
tion is B-hydroxylation of aspartic acid reside 71, possibly
required for calcium-dependent membrane binding which is
independent of the binding activity of the Gla regions.
There are a variety of clinical Situations for which protein
C may prove beneficial. It may serve as replacement therapy
in homozygous deficient infants Suffering from purpura
fulminans neonatalis. Other conditions include patients with
a previous history of warfarin-induced skin necrosis who
must have additional warfarin therapy, heparin-induced
thrombocytopenia, Septic shock for prevention of intravas
cular coagulation and organ damage, and for fibrinolytic
therapy, as protein C can protect t?A from plasma inhibitor
proteins. Table 1 represents one estimate of the number of
individual cases of Several clinical Syndromes which might
be treated by purified protein C. Because there has not been
Sufficient material available from plasma for clinical trials
until recently, these data are necessarily based on an incom
plete assessment of the therapeutic potential for protein C.

5-50
10-100
10-100

Per Treatment

Total

Human protein C (hPC) is a 62 kD, disulfide-linked

Several regions of the molecule have important implica
tions for function as an anticoagulant in the regulation of
hemostasis. The amino terminal portion of the light chain

Total U.S.

Septic Shock
Thrombolytic Therapy *
Hip Replacement

Protein C is an important component of the coagulation
System that has strong anticoagulant activity. In its active
form it is a Serine protease that proteolytically inactivates
Factors V, and VIII.

the presence of thrombomodulin, cleavage of an Arg-Leu
bond in the amino terminal portion of the heavy cain releases
a 12 amino acid peptide. See generally Gardiner & Griffin in
PROGRESS IN HEMATOLOGY, Vol. XIII at page 265-278

# Treatments

Indication

BACKGROUND OF THE INVENTION

heterodimer consisting of a 25 kD light chain and a 41 kD
heavy chain which circulates as an inactive Zymogen in
plasma. At the endothelial cell Surface it is activated to

Dose (mg)

Nat'l Acad. Sci. USA 80: 1802 (1983). Beta-hydroxylation
50

may be important to protein C activity. Although its function
is not known it has been Suggested that it may be involved

in Y-carboxyglutamic acid independent Cabinding, and it
may be required for full anti-coagulant activity.
Human protein C is also glycosylated. Kisiel, J. Clin.

Invest. 64: 761 (1979). It contains four potential N-linked

55

60

glycosylation sites, located at ASn97, ASn248, ASn313 and
ASn329. The first three signals match the consensus ASn
X-Ser/Thr glycosylation Sequences, and are actively glyco
Sylated. There is an atypical glycosylation signal at ASn329,
Asn-X-Cys-Ser. The ASn329 signal is glycosylated in
bovine protein C, but it is not yet known if ASn329 is
glycosylated in human protein C. Miletich et al., J. Biol.

Chem. 265: 11397 (1990). The pattern and extent of glyco

65

Sylation can alter the physiological activity of protein C.
Until recently, human protein C for experimental and
therapeutic use was obtained exclusively from human
plasma. Unfortunately, the quantity of protein that can be
obtained from human Serum is limited. Furthermore, prod

5,831,141
4
Stantially the human protein C gene from 21 basepairs
upstream of the protein C start codon to the Nhe site in the
3' end of the protein C gene, or a variant thereof is among
the most highly preferred.
In a particularly preferred embodiment, the exogenous
DNA sequence comprises a DNA sequence consisting essen
tially of the 5' 4.2 kb Sau3A-Kpn1 promoter fragment of the
mouse whey acidic protein promoter ligated directly or by a
linker to a fragment of the human protein C gene beginning
21 basepairs upstream of the protein C Start codon and
ending at the Nhe site in the 3' end of the protein C gene.
In accordance with another aspect of the present
invention, there has been provided a process for the pro

3
ucts derived from human serum pose difficulties of
reliability, purity and Safety.
The expression of therapeutic proteins by recombinant
DNA technology is an attractive alternative to plasma pro
duction of protein C, in that it eliminates the risk of potential
contamination with blood-borne viruses and theoretically
provides an unlimited Supply of product. But the complexity
of the post-translational modifications, as discussed above,
has rendered problematic the production of commercially
uSeable amounts of Suitably active protein C by expression
in a heterologous host.
In fact, it has not been possible to produce Vitamin
K-dependent proteins like protein C at Sufficiently high
levels in an active form, despite efforts to do So using a
variety of expression Systems. See Grinnell et al. in Volume

15

11 of ADVANCES IN APPLIED BIOTECHNOLOGY

SERIES, Chapter 3 (Gulf Publishing Co.). In particular, any

prospect for expressing protein C in mammary glands of a
transgenic animal and Secreting the protein into milk, See,

e.g., U.S. Pat. No. 4,873,316 (1989), is clouded by the fact

that protein C is normally synthesized in the liver. Even
HepG2 cell lines derived from human liver produce aberrant
In this regard, it has been observed that a mouse mam

25

protein C expressed protein C that was only 30-40% active.
Further analysis revealed that the protein C contained dimin
ished levels of Y-carboxyglutamic acid and little, if any,
B-hydroxyaspartic acid. Suttie et al., Thrombosis Res. 44:

129 (1986). These experiments indicate that mouse mam

mary epithelial cells cannot perform all of the post
translational modifications necessary for obtaining Suitably
active protein C, which in turn casts doubt on the likelihood
of obtaining Such protein C from the milk of a transgenic

35

mammal.
SUMMARY OF THE INVENTION

It is therefore an object of the present invention to provide
a transgenic animal which produces in its milk recombinant
protein C that comprises a Significantly higher percentage of
active protein than has been achieved heretofore.
It is another object of the present invention to provide a
proceSS for producing protein C in commercially useable
amounts, by means of a transgenic mammal.
In accomplishing the foregoing objects, there has been
provided, in accordance with one aspect of the present
invention, a transgenic mammal containing an exogenous
DNA sequence Stably integrated in its genome, wherein the
exogenous DNA sequence comprises a promoter operably
linked to a DNA sequence encoding a polypeptide having
protein C activity and a signal peptide, wherein the promoter
is specifically active in mammary cells, particularly mam
mary epithelial cells, and the Signal peptide is effective in
directing the secretion of the protein C into the milk of the
transgenic mammal.
In a preferred embodiment, the promoter is a whey acidic
protein promoter. In a highly preferred embodiment the
promoter comprises substantially the 5' 4.2 kb Sau3A-Kpn1
promoter fragment of the mouse whey acidic protein gene,

40

45

50

ing the polypeptide from the milk.
In a highly preferred embodiment of this aspect of the
invention, the promoter comprises substantially the 5' 4.2 kb
Sau3A-Kpn1 promoter fragment of the mouse whey acidic
protein gene, or a variant thereof.
Additionally, in a preferred embodiment the DNA
Sequence encoding a polypeptide having human protein C
activity comprises portions of the non-coding regions of the
human protein C gene. In a particularly preferred embodi
ment of this type the DNA sequence gene comprises Sub
Stantially the human protein C gene from 21 basepairs
upstream of the protein C start codon to the Nhe site in the
3' end of the protein C gene, or a variant thereof is among
the most highly preferred.
In addition, is certain a particularly preferred
embodiment, the exogenous DNA sequence comprises a
DNA sequence consisting essentially of the 5' 4.2 kb Sau3A
Kpn1 promoter fragment of the mouse whey acidic protein
promoter ligated directly or by a linker to a fragment of the
human protein C gene beginning 21 basepairs upstream of
the protein C start codon and ending at the Nhe site in the
3' end of the protein C gene.
In accordance with Still another aspect of the present
invention, a process has been provided for producing trans

genic animals, comprising the steps of (A) providing a
mixture containing a genetic construct; (B) Subjecting the
mixture to anion-exchange high performance liquid chro
matography to obtain purified genetic construct; and there

after (C) microinjecting an aqueous buffer Solution contain
a preferred embodiment, step (B) comprises applying the

ing the purified genetic construct into an animal embryo. In
55

60

or a variant thereof.

In another aspect in a preferred embodiment the DNA
Sequence encoding a polypeptide having human protein C
activity comprises portions of the non-coding regions of the
human protein C gene. In a particularly preferred embodi
ment of this type the DNA sequence gene comprises Sub

a transgenic mammal characterized by an exogenous DNA
Sequence Stably integrated in its genome, wherein the exog
enous DNA sequence comprises a promoter operably linked
to a DNA sequence encoding a polypeptide having protein
C activity and a signal peptide, the promoter being Specifi
cally active in mammary cells and the Signal peptide being
effective in directing the Secretion of the protein C into the

milk of the transgenic mammal; (B) producing milk from the
transgenic mammal, (C) collecting the milk, and (D) isolat

forms of protein C. Marlar & Fair (1985).
mary epithelial cell line (C-127) transfected with a bovine
papilloma virus (BPV) vector bearing the cDNA for human

duction of protein C, comprising the steps of (A) providing

65

mixture to an anion-exchange high performance liquid chro
matography column, eluting the genetic construct from the
column, and then Subjecting the genetic construct to a
Second anion-exchange high performance liquid chromatog
raphy.
In a preferred embodiment of this aspect of the invention,
the double-stranded DNA is selected from the group con
Sisting of a double-Stranded DNA comprising Substantially
the 5' 4.2 kb Sau3A-Kpn1 promoter fragment of the mouse
whey acidic protein promoter, a double-Stranded DNA com
prising Substantially a fragment of the human protein c gene
beginning 21 basepairs upstream of the protein C Start codon

5,831,141
S
and ending at the Nhe site in the 3' end of the protein C
gene, and a double-Stranded DNA comprising a DNA
Sequence consisting essentially of the 5' 4.2 kb Sau3A-Kpn1
promoter fragment of the mouse whey acidic protein pro
moter ligated directly or by a linker to a fragment of the
human protein C gene beginning 21 basepairs upstream of
the protein C start codon and ending at the Nhe site in the
3' end of the protein C gene.
In accordance with yet another aspect of the invention,
there has been provided a process for the production of a
polypeptide in the milk of a transgenic non-human mammal,
comprising the Steps of providing a non-human transgenic
mammal characterized by an exogenous DNA sequence
Stably integrated in its genome, wherein Said exogenous
DNA sequence comprises substantially the 5' 4.2 kb Sau3A
- Kipn1 promoter of the mouse whey acidic protein gene, or
a variant thereof, operably linked to a DNA sequence
encoding Said polypeptide and a signal peptide, Said pro
moter being Specifically active in mammary cells and Said
Signal peptide being effective in directing the Secretion of
Said polypeptide into the milk of Said transgenic mammal;
producing milk from Said transgenic mammal; collecting
Said milk, and isolating Said polypeptide from Said milk. In
a particularly preferred embodiment of this aspect of the
invention, the exogenous DNA sequence comprises the 5'
4.2 kb Sau3A - Kipn1 promoter fragment of the mouse whey
acidic protein promoter.
The accordance with yet another aspect of the invention
there has been provided a transgenic non-human mammal
containing an exogenous DNA sequence Stably integrated in
its genome, wherein the exogenous DNA sequence com
prises substantially the 4.2 kb Sau3A-Kpn1 whey acidic
protein promoter fragment, or a variant thereof, operably
linked to a DNA encoding a polypeptide whereby the protein
is expressed specifically in mammary cells of the transgenic
mammal and the protein comprises a signal peptide, the
peptide being effective in directing the Secretion of the
protein into the milk of Said mammal. In a particularly
preferred embodiment of this aspect of the invention, the
exogenous DNA sequence comprises the 5' 4.2 kb Sau3A
Kpn1 promoter fragment of the mouse whey acidic protein

6
FIG. 4 is a graph that shows the results of an APTT assay
to determine human protein C anti-coagulant activity in
whey obtained from a transgenic mouse.

FIG. 5 is a graph that shows the results of Ca"-dependent
and Cat"-independent light chain capture ELISAS which
demonstrate that the Y-carboxyglutamic acid in human pro
tein C in whey from transgenic mouse Y52 is similar to that
in protein C derived from human Serum.
FIG. 6 is a Schematic diagram representing a highly
preferred murine WAP-human protein C construct. In this
construct, a 4.2 kb 5’ murine whey acidic protein promoter
fragment is linked to a 9.4 kb genomic fragment encoding
human protein C which includes the 400 bp extending from
15

25

35

40

45

50
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linked immunosorbent assay (ELISA) of human protein C in
milk obtained from a transgenic mouse.

DETAILED DESCRIPTION OF THE
INVENTION

Notwithstanding past failures to express recombinant
protein C with Suitably high activity in several different
expression Systems, including transformed mammary cells,
it has been discovered that recombinant protein C charac
terized by a high percentage of active protein can be
obtained in the milk of transgenic animals that incorporate
DNAS according to the present invention. Transgenic ani
mals of the present invention are produced by introducing
into developing embryos DNA that encodes protein C, Such
that the DNA is stably incorporated in the DNA of germ line
cells of the mature animal and inherited in normal, mende
In accordance with the invention, DNAS can be intro

60

reaction (PCR) primer pairs useful to detect WAP-protein C
DNAS in transgenic animals.
FIG. 3 is a graph that shows the results of an enzyme

FIG. 8 shows the amidolytic activity in samples of whey
from transgenic mice. Panel A ShowS amidolytic activity of
whey proteins resolved by PAGE under native conditions.
Panel B shows the proteins detected by anti-hPC antibodies
in a Western blot of an identical gel, Visualized using
4-chloro-1-naphthol. Lanes were loaded with approximately
50 ug of protein. Lane 1 contained purified human protein C.
Lane 2 contained a Sample form a non-transgenic mouse.
Lanes 3 through 8 contained, respectively, Samples from
transgenic mice 7.5.4, 7.2.2, 5.2.12, 4.2.10, 6.4 and 5.4.

lian fashion.

FIG. 1 is a schematic diagram representing WAPpCI, a
construct which contains cDNA encoding human protein C
gene at the unique Kpn1 site.
FIG. 2 is a Schematic representation of polymerase chain

diagram.
FIG. 7 is a photograph showing the results of western
analyses of human protein C production in the milk of
transgenic animals. Panel A shows the proteins in whey
Samples resolved by PAGE under reducing conditions and
visualized by silver staining. Panel B shows the proteins
detected by anti-human protein C antibodies in a western
blot of an identical gel, Visualized by chemiluminescence.
Lanes were loaded with approximately 5 lug of protein.
Lanes 1 through 6 contained, respectively, Samples from
transgenic mice 5.4, 6.4, 4.2.10, 5.2.12, 7.2.2 and 7.5.4.
Lane 7 contained a Sample from a non-transgenic mouse.
Lane 8 contained purified human protein C. “SC'-single
chain hPC, “HC'-heavy chain forms of hPC, “LC"-light
chain hPC.

BRIEF DESCRIPTION OF THE FIGURES

inserted into an intact murine whey acidic protein (WAP)

human protein C gene. The sequence of the WAP-hPC

junction (SEQ ID NO: 1) is shown above the schematic

promoter.

In certain preferred embodiments of various aspects of the
invention, the transgenic mammal is mouse, rabbit, pig,
sheep or goat. In Some most highly preferred embodiments
the animal is pig or sheep.
Other objects, features and advantages of the present
invention will become apparent from the following detailed
description. It should be understood, however, that the
detailed description and the Specific examples, while indi
cating preferred embodiments of the invention, are given by
way of illustration only, Since various changes and modifi
cations within the Spirit and Scope of the invention will
become apparent to those skilled in the art from this detailed
description.

the end of exon VIII to the Nhe site in the 3' end of the

65

duced into embryos by a variety of means to produce
transgenic animals. For instance, totipotent or pluripotent
Stem cells can be transformed by microinjection, calcium
phosphate mediated precipitation, liposome fusion, retrovi
ral infection or by other means. The transformed cells can
then be introduced into embryos and incorporated therein to
form transgenic animals. In a preferred method, developing
embryos can be infected with retroviral vectors and trans
genic animals can be formed from the infected embryos. In

5,831,141
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the most preferred method, however, the DNAS of the
invention are injected into embryos, preferably at the Single
cell Stage, which are allowed to develop into mature trans
genic animals.
Suitable protein C-encoding DNA used for producing
transgenic animals in this fashion can be obtained using
human liver tissue as a Source for cloning the hPC gene. The
DNA coding for protein C can be fused, in proper reading
frame, with appropriate regulatory signals, as described in
greater detail below, to produce a genetic construct which is
then amplified, for example, by propagation in a bacterial
vector, according to conventional practice.
The amplified construct is thereafter excised from the
vector and purified for use in microinjection. The purifica
tion is preferably accomplished by means of high perfor
mance liquid chromatography (HPLC), which rids the con
Struct of contamination from the bacterial vector and from
polysaccharides typically present when other techniques,
Such as conventional agarose electroelution, are used. The
preferred HPLC method entails sorbing the construct onto
an anion-exchange HPLC Support and Selectively eluting the
construct from the Support, preferably with an aqueous
Sodium chloride Solution, thereby to eliminate contamina
tion from the vector. (Elution may be effected by other
means, Such as a pH gradient.) Alternatively but less
preferably, the excised construct can be purified by ultra
centrifugation through an aqueous Sucrose gradient.
Since it is preferable that the construct have the minimum
amount of impurities, more than one cycle of HPLC or other
purification is advantageous. In particular, the use of HPLC
purified DNA for microinjection, as described above, allows
for remarkably high transformation frequencies, on the order
of 20% or more in both mice and pigs.
All lactating animals, that is, all mammals, are Suitable for
use according to the present invention. Preferred mammals
include mice, rats, rabbits, pigs, sheep, goats and cows.
More particularly, mice, pigs, sheep and cows are preferred.
Most preferred at present are mice, pigs and sheep.
DNA constructs useful in the present invention provide a
DNA sequence encoding protein C operably linked to all the
cis-acting Signals necessary for mammary tissue specific
expression of protein C, post-translational modification of
protein C, Secretion of protein C into milk, and full biologi
cal activity of protein C.
DNAS useful in the invention include genomic or comple
mentary DNAS that encode naturally occurring protein C. In
a preferred embodiment DNAS encoding human protein C
are employed, including CDNA and genomic DNAS. DNAS
encoding protein C from other Species may also be used,
Such as the protein C encoded by rats, pigs, sheep, cows and
chimpanzees.
In a particularly preferred embodiment, human genomic
DNAS encoding protein C are employed. Among the most
highly preferred human genomic DNAS is the fragment of
the human protein C gene beginning 21 basepairs upstream
of the protein C start codon and ending at the Nhe site in the
3' end of the protein C gene. This fragment, approximately
9.4 kb long, contains regulatory elements that engender high
expression of human protein C in the milk of non-human
transgenic mammals. Some of these regulatory elements are
the AUG start codon, donor and acceptor Splice Signals, the
Secretion peptide, and the translation termination, transcrip
tion termination and polyadenylation Signals.
It will be appreciated that there may be additional regu
latory elements in the fragment that aid the production of
transgenic non-human mammals that express high levels of

8

15

protein C in their milk. Some of these signals may be
transcription or translation control Signals, or those associ
ated with transport out of the cell. Other Signals may play a
role in efficient chromosomal integration or Stability of the
integrated DNA. Various regions of the fragment may con
tain Such Signals, Such as the region between the end of exon
VIII and the Nhe site in the 3' end of the protein C gene.
It will be readily appreciated that deletional and other
mutational techniques may be employed to elucidate further
all the Signals in this fragment that confer high levels of
protein C expression in the milk of transgenic animals.
It will also be appreciated that the 9.4 kb protein C
fragment described above can be modified using recombi
nant DNA techniques in an almost infinite number ways. 3'
or 5" portions of the protein C gene can be added, or a few
bases at either end may be removed. Introns can be removed
or added. Portions of one or more introns can be deleted.

Additional DNA can be inserted into them. The sequences of
the introns can be altered. Exons can be modified in accor
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dance with the discussion of modified protein C molecules
set forth below. Most such modified forms of the preferred
genomic protein C fragment will not be significantly
changed in their ability in transgenic animals to engender the
production of milk-born protein C. Thus, these substantially
Similar fragments will be equivalent in the invention to the
particularly disclosed 9.4 kb fragment of human protein C
that begins 21 basepairs upstream of the protein C Start
codon and ends at the Nhe site in the 3' end of the protein
C gene.
Modified protein C Sequences also can be employed in the
present invention. Useful modifications in this context
include but are not limited to those that alter the post
translational processing of protein C, that alter the size of
protein C, that fuse protein C or portions thereof to portions
of another protein, or that alter the active Site of protein C.
Preferred modifications include those that provide an acti
vated protein C and those that provide for activation of
protein C in the absence of thrombomodulin. In a preferred
embodiment, modified forms of human protein C are
employed.
Such modifications can be introduced into protein C by
techniques well known to the art, Such as the Synthesis of
modified genes by ligation of Overlapping oligonucleotide,
and by introducing mutations directly into cloned genes, as
by oligonucleotide mediated mutagenesis, inter alia.
The cis-acting regulatory regions useful in the invention
include the promoter used to drive expression of the protein
C gene. Promoters useful in the invention are active in
mammary tissue. Particularly useful are promoters that are
Specifically active in mammary tissue, i.e., are more active
in mammary tissue than in other tissues under physiological
conditions where milk is synthesized. Most preferred are
promoters that are both Specific to and efficient in mammary
tissue. By “efficient' it is meant that the promoters are Strong
promoters in mammary tissue that can Support the Synthesis
of large amounts of protein for Secretion into milk.
Among Such promoters, the casein, lactalbumin and lac
toglobulin promoters are preferred, including, but not lim
ited to the Cl-, 3- and Y-casein promoters and the
a-lactalbumin and Y-lactoglobulin promoters. Preferred

among the promoters are those from rodent (murine and rat),

pigs and sheep, especially the rat B-casein promoter and the
sheep f-lactoglobulin promoter. The most preferred promot
65

ers are those that regulate a whey acidic protein (WAP) gene,
and the most preferred WAP promoter is the murine WAP
promoter.
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A most highly preferred promoter is the 4.2 kb Sau3A
Kpn1 promoter fragment of the mouse whey acidic protein
promoter. It has been found that this fragment is highly
efficacious in directing the production of high levels of a
protein in the milk of a transgenic animal. In the case of
human protein C this mouse whey acidic protein promoter
fragment has engendered the production of active protein C
in the milk of transgenic animals in concentrations above 4

5

mg/ml (by polyclonal ELISA).

It will be readily appreciated, as for the 9.4 kb protein C
genomic DNA discussed above, the 4.2 kb Sau3A-Kpn1
whey acidic protein promoter fragment can be modified by
recombinant DNA techniques readily available to those of
ordinary skill in the art. Thus, the fragment can be shortened,
keeping in mind that the 2.4 kb 5’ WAP promoter fragment
gives rise to very much lower yields. It can be lengthened to
include more of the whey acid protein promoter region or
other portions of the whey acid protein gene. Portions can be
removed, and DNA can be inserted into the fragment.
Internal bases can be altered. In the majority of cases these
alternatives will not affect the ability of this promoter
fragment to induce very high levels of expression. Frag
ments modified in this way, giving the expected high yields
of protein in transgenic milk, are Substantially similar vari
ants of the 4.2 kb 5’ promoter fragment. They also are useful
in the present invention and are functionally equivalent in
this respect to the 4.2 kb Sau3A-Kpn1 whey acidic protein
promoter fragment itself.
Also important to the invention are the Signal Sequences
that direct Secretion of protein into the milk of the transgenic
animal. In this regard, both endogenous and heterologous
Signal Sequences are useful in the invention. Generally, the
Signal peptides of proteins normally Secreted into milk are
useful in the invention. The Signal Sequences of proteins that
occur in high concentration in milk are particularly
preferred, Such as the Signal peptides of the caseins, lactal
bumins and lactoglobulins, including, but not limited to the
Signal peptides of the Cl-, 3- and Y-caseins and a-lactalbumin
and B-lactoglobulin. More particularly, the Signal Sequence
of whey acidic protein is preferred, most particularly the
Signal Sequence of the murine whey acidic protein.
Also particularly preferred are the Signal peptides of
Secreted coagulation factors. Especially preferred in this
regard are the Signal peptides of protein C, and t-PA. Most
especially preferred is the Secretion signal of human protein

rodents (mice and rats), pigs and sheep. Even more particu
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Among the Sequences that regulate transcription that are
useful in the invention, in addition to the promoter
Sequences discussed above, are enhancers, Splice Signals,
transcription termination Signals and polyadenylation sites,
among others. Particularly useful regulatory Sequences
increase the efficiency of mammary cell Specific expression
of protein C in transgenic animals.
Especially useful in this regard are the other transcription
regulatory Sequences of genes expressed at high levels in
mammary cells, Such as the Cl-, 3- and Y-casein genes and the
C.-lactalbumin and B-lactoglobulin genes mentioned above.
Preferred Sources for regulatory Sequences in this regard are

rodents (mice and rats), pigs and sheep.
Exemplary of preferred regulatory Sequences are those
asSociated with the rat B-casein gene and the sheep
B-lactoglobulin gene, respectively. The regulatory
Sequences most preferred for use in the present invention are
those associated with whey acidic protein genes. Particularly
preferred in this context are regulatory Sequences of the
murine whey acidic protein.

Among the Sequences that regulate translation, in addition
to the Signal Sequences discussed above, are ribosome
binding Sites and Sequences that augment the Stability the
protein C mRNA. Especially useful are the translation
regulatory Sequences of genes expressed at high levels in
mammary cells. For instance, the regulatory Sequences of
the Cl-, 3- and Y-casein genes and the a-lactalbumin and
B-lactoglobulin genes are preferred, especially those from

50

larly preferred are the regulatory Sequences of rat B-casein
and the sheep B-lactoglobulin genes.
The most preferred translational regulatory Sequences of
the invention are those of the whey acidic protein and the
protein C genes. And the most particularly preferred regu
latory Sequences are those of the murine whey acidic protein
and human protein C, including human genomic protein C
and human protein C CDNA constructs, and including
human protein C cl)NA constructs that contain intron
Sequences. Among these, the most highly preferred are the
regulatory Sequences of the human protein C gene in the
region beginning 21 basepairs upstream of the protein C
start codon and ending at the Nhe site in the 3' end of the
protein C gene, and the regulatory Sequences of the mouse
whey acidic protein promoter in the 5' 4.2 kb Sau3A-Kpn1
promoter fragment of the mouse whey acidic protein
promoter, most particularly when they are used together.
Especially useful in the present invention are Sequences
that advantageously modulate post-translational modifica
tions of protein C, Such that the protein C produced in the
transgenic animals of the invention is active. In particular,
the genomic Sequences of the human protein C gene are
preferred.
Thus, in accordance with the present invention a DNA
Sequence that encodes protein C is operably linked to
cis-acting regulatory Sequences which allow for efficient
expression of protein C in milk. The resulting chimeric DNA
is introduced into a mammalian embryo, where it integrates
into the embryonic genome and becomes part of the heri
table genetic endowment of all the cells, including the germ
line cells, of the adult which develops from the embryo. The
protein C which is expressed in the mammary tissue and
Secreted into the milk of a transgenic mammal obtained in
this manner displays a Surprisingly high percentage of active
protein, as measured by enzymatic and coagulation
inhibition assays which are conventionally employed to
detect protein C activity, Such as ELISAS, chromogenic
activity assays and coagulation inhibition assayS. Levels of
active protein on the order of 80% to 90% or more are
characteristic of the protein C expressed in accordance with
the present invention.
Obtaining milk from a transgenic animal within the
present invention is accomplished by conventional means.

McBurney et al., J. Lab. Clin. Med. 64: 485 (1964). The
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protein C contained in Such milk can be purified by known
means without unduly affecting activity. One Suitable
approach to purification in this regard is immunoaffinity
chromatography. Alternatively, the expressed protein C can
be isolated from the milk by other conventional means, for
instance, by the method of Kisiel, J. Clin. Invest. 64: 761

(1979). In any event, it is preferred that protein C produced

in milk pursuant to the present invention should be isolated
as Soon as possible after the milk is obtained from the
transgenic mammal, thereby to mitigate any deleterious
65

effect(s) on the stability of the protein.
The present invention is further described by reference to
the following, illustrative examples.
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Second time. Results reported below, for both pigs and mice,
were generated using HPLC-purified DNA.
DNA concentrations were determined by agarose gel
electrophoresis by Staining with ethidium bromide and com
paring the fluorescent intensity of an aliquot of the DNA
with the intensity of Standards. Samples were then adjusted
to 10 ug/ml and stored at -20°C., prior to microinjection.

EXAMPLE 1.

DNAS Useful for Expressing Protein C in
Transgenic Animals
The entire murine WAP gene including 2.5 kb of 5'
untranslated Sequence and 3' untranslated regions was
cloned by standard methods. See Campbell et al., Nucleic

Acids Res. 12:8685 (1984). The human placental cDNA for

human protein C was obtained from C. Shoemacker. Human
genomic DNAS encoding protein C were cloned by Standard
methods from a human placental genomic library. The 9.4 kb
fragment was assembled from two genomic clones and a
Sali, Mse ended 60 bp synthetic oligonucleotide that was
added to the 5' end of the gene.
Standard recombinant DNA techniques were employed to
generate the vectors and expression constructs of the pre
ferred embodiments, and for other manipulations of DNA,

EXAMPLE 3
1O

Transgenic Animals

(1) Mice
15

as set forth below. See Sambrook et al., MOLECULAR

and a pico-injector driven by N (Narashigi).
Fertilized mouse embryos were Surgically removed from
the oviducts of Superovulated female CD-1 mice and placed
25

were then rinsed in new M2 medium, and transferred into

lation.

(2) WAPpC2

35

and 3' ends.
EXAMPLE 2

Preparation of DNAS for Microinjection
DNA for microinjection was prepared according to the
procedures described below for DNA from WAPpC1.
The 9 kb WAPpC1 fragment was removed from the vector
with the restriction enzyme EcoRI. After digestion with
EcoRI the solution containing the WAPpC1 DNA was
brought to 10 mM magnesium, 20 mM EDTA and 0.1% SDS
and then extracted with phenol/chloroform. DNA was pre
cipitated from the aqueous layer with 2.5 volumes of ethanol
in the presence of 0.3 M sodium acetate at -20° C. over
night. After centrifugation, the pellet was washed with 70%
ethanol, dried, and resuspended in Sterile distilled water.
DNA for microinjection was purified by HPLC. The
digested DNA was precipitated with isopropanol and then
dissolved in TE buffer at 0.3 ug/ml. Fragments were purified
by HPLC using a Waters GEN FAX PAC HPLC column.
The column was run isocratically using a buffer consisting

of 25 mM Tris-HCl (pH 7.5), 1 mM sodium EDTA, and
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0.63M NaCl. This is the minimum NaCl concentration that

will elute the large construct fragment and results in the best
resolution from the Smaller vector fragment which elutes
just prior to the construct fragment. About 15 lug of digested
DNA was loaded on the column at a time. The construct

fragment Samples from all of the chromatographic runs were
then pooled, reprecipitated, and run through the column a

into M2 medium. Cumulus cells were removed from the

embryos with hyaluronidase at 300 tug/ml. The embryos

(FIG. 1). This WAP protein C construct was ligated into a
blueScribe vector (Stratagene) to facilitate further manipu
WAPpC2 is similar to WAPpC1, comprising the entire
murine WAP gene and human protein C clNA but differs
from WAPpC1 in lacking artefactual 5' flanking sequences
present in WAPpC1 as a result of cloning procedures used to
make that construct. Specifically, 33 bp 5' to the protein C
ATG and 118 “A’s” at the 3' end of the protein C cDNA were
removed by PCR, and new Kipni sites were added at the 5'

EMBRYO (Cold Spring Harbor Press 1986). The proce

dures employed are outlined below.
Glass needles for micro-injection were prepared using a
micropipet puller and microforge. Injections were per
formed using a Nikon microscope having Hoffman Modu
lation Contrast optics, with Narashigi micromanipulators

CLONING, A LABORATORY MANUAL, Vol. 1-3 (Cold
Spring Harbor Press 1989).
(1) WAPpC1
A DNA construct called WAPpC1 was made, consisting
of the entire murine WAP gene containing one copy of
human protein C cDNA inserted at the unique KpnI site, 24
base pairs 3' of the transcriptional start site of the WAP gene

Transgenic mice were produced essentially as described
by Hogan et al., MANIPULATING THE MOUSE
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M16 medium for storage at 37 C. prior to injection.
After injecting the DNA solution into the male
pronucleus, embryos were implanted into avertin
anesthetized CD-1 recipient females made pseudo-pregnant
by mating with vasectomized males. Embryos were allowed
to come to term and the newborn mice were analyzed for the
presence of the transgene as described below.
(2) Pigs
Embryos were recovered from the oviduct. They were
placed into a 1.5 ml microfuge tube containing approxi
mately 0.5 ml embryo transfer media (phosphate buffered
saline +10% fetal calf serum, Gibco BRL). These were then
centrifuged for 12 minutes at 16,000xg RCF (13.450 RPM)
in a microcentrifuge (Allied Instruments, model 235C).
Embryos were removed from the microfuge tube with a
drawn and polished Pasteur pipette and placed into a 35 mm
petri dish for examination. If the cytoplasm was still opaque
with lipid such that pronuclei are not visible, the embryos
were centrifuged again for 15 minutes. Embryos to be
microinjected were placed into a microdrop of media
(approximately 100 ul) in the center of the lid of a 100 mm
petri dish. Silicone oil was used to cover the microdrop and
fill the lid to prevent media from evaporating. The petri dish
lid containing the embryos was set onto an inverted micro
Scope (Carl Zeiss) equipped with both a heated Stage and
Hoffman Modulation Contrast optics (200x final
magnification). A finely drawn (Kopf Vertical Pipette Puller,
model 720) and polished (Narishige microforge, model
MF-35) micropipette was used to stabilize the embryos
while about 1-2 picoliters of HPLC-purified DNA solution
containing approximately 200-500 copies of DNA construct
was delivered into the male pronucleus with another finely
drawn micropipette. Embryos Surviving the microinjection
process as judged by morphological observation were
loaded into a polypropylene tube (2 mm ID) for transfer into
the recipient pig.
(3) Other Animals
Methods for microinjection of other animal Species are
similar to the methods set forth above.

5,831,141
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young for approximately 5 hours. They were then anesthe

13
EXAMPLE 4

tized with 0.4 ml avertin at 2.5% (I.M.), and 0.2 ml oxytocin
was then administered at 2.5 IU/ml (I.P) to permit release of
the milk. A milking device consisting of a vacuum pump (2.5
psi) and Syringe with an eppendorf tip was used to direct

Assessment via PCR of WAP/hPC Constructs in

Transgenic Animals

(1) Preparation of DNA form Transgenic Animals

milk into an eppendorf tube. During collection, milk was
placed on ice until all Samples were obtained.
To prepare whey, milk was diluted 1:1 with TS buffer

DNA can be prepared from tissue of a transgenic animal
of any species by the method exemplified below for mice.
A 5 mm piece of mouse tail was removed from young,

potentially transgenic mice at weaning (3 weeks of age),
minced, and treated with proteinase K and SDS at 37 C.

(0.03M Tris pH 7.4; 0.06 NaCl) and centrifuged in a

overnight. The mixture was then incubated with DNase-free
RNase at 37 C. for 1-2 hours. DNA was precipitated from

centrifugation the tubes were put on ice, and the whey was
collected with an 18 gauge needle, leaving the casein pellet
and upper cream layer in the tube. To remove Solids or cream
that co-transferred during the initial recovery, the whey
obtained from the first centrifugation was Subjected to a
second spin at 12,000 rpm for 30 minutes at 4 C. in a
TMA-4 rotor in a Tomy MTX-150 centrifuge. Following the
Second Spin the tubes were place on ice and the whey was

TLA-100 rotor in a Beckman TL-100 table top ultracentri

fuge at 51,000 rpm (89,000xg) for 30 minutes at 4°C. After

the mixture with sodium acetate and ethanol at -20° C.

overnight, collected by centrifugation, washed in 70% etha
nol and dried. The dried DNA pellet was used directly for
PCR. In some cases the mixture was extracted extensively
with phenol/chloroform prior to ethanol precipitation.
Essentially the same technique was used to prepare DNA
from pigs, and the same or similar techniques can be used to
prepare DNA from other animals.

15

recovered as before.
EXAMPLE 6

(2) Oligonucleotide Probes used in the PCR Assay
Oligonucleotide pairs were used to prime polymerase
chain reactions that detected the presence of WAP-protein C
constructs in the transgenic animals. These pairs and their
extension products are shown schematically in FIG. 2 Oli
gonucleotide pairs that bridge the region from the WAP
sequences 5' of the KpnI site and the endogenous WAP
Sequences which naturally lie 3' of the Kipni Site also
provided positive controls in mice.

(3) PCR Reaction Conditions and Product Analysis
PCR reactions were performed using an annealing tem
perature of 58 C., a denaturation temperature of 94 C., and
an extension temperature of 72 C., using 100 ng of oligo
primers and 50 ng of (genomic) template DNA per reaction,

25

35

and cycling through the temperatures 40 times using an

automatic temperature cycler (M.J. Research).
PCR reactions were analyzed by running 20% of the
reaction products on agarose gels and identifying fragment
sizes by comparison with marker DNA fragments.

40

5 of the 16 mice which were tested.

5x with TET buffer, horse radish peroxidase (HRP)45

Whey Acid Protein-Protein C Construct Integration Rates
# Tested

# Positive

Integration Rate

Mice

105

3O

29%

Pigs

23

5

22%

55

5/16 Tested = 31%
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EXAMPLE 5

Preparation of Milk and Whey from Transgenic

(A) Mice: Lactating mice were milked an average of 3
times per week. The mice were first Separated from their

ing one tablet of OPD in 20 ml of 0.1M citrate-phosphate

buffer (pH 5.0), were added to each well. After 10 minutes

at room temperature the reaction was Stopped with 1N
sulfuric acid. The extent of the reaction was determined by
measuring product absorption at 490 nm.
The result of an ELISA analysis of the milk from one

transgenic mouse (Mouse No. 5) is shown in FIG. 3.

Mendelian Transmission in Transgenic Mice

Animals

conjugated to rabbit anti-hPC was diluted 1:1000 in 0.1%
BSA/TET and 100 ul was added per well and incubated for
2 hours at room temperature, with Shaking at 100 rpm. After
again washing 5 times with TET buffer, 100 ul of orthophe

nyldiamine (OPD), from a stock solution made by dissolv

50

TABLE 2

Animal

with TET buffer (0.01M Tris pH 7.5; 0.01M EDTA; 0.02%
tween-20, pH 7.45) and then blocked with 1% BSA in PBS
using 400 ul per well for 1 hour at 37 C. Plates were again
washed with TET buffer (5x) followed by addition of 100 ul
of Sample whey or normal whey Spiked with human protein
C from plasma, to generate a Standard curve. After washing

(4) Results of PCR Analysis of Transgenic Animals
PCR analysis of potentially transgenic mice and pigs
which developed from embryos microinjected with
WAPpC1 and WAPpC2 constructs are summarized in Table
2. The results show that WAPpC constructs frequently
integrated into the embryonic genomes of both mice and
pigs. Furthermore, mendelian transmission was observed in

Determination by ELISA of Protein C Produced by
Transgenic Mammals
An ELISA was used to measure the amount of protein C
protein produced by transgenic animals in their milk or
whey. Two monoclonal antibodies, 7D7B10 and 12A8, and
a polyclonal antiserum were used in the ELISAS, and a
variety of other protein C specific antibodies could be
employed. The 7D7B10 monoclonal is specific for the NH
terminus of the light chain of protein C. 12A8 is specific for
the reactive site on the heavy chain of protein C.
Microtiter plate wells were coated overnight at 4 C. with
3 ug/ml of monoclonal antibody in 50 ul of 0.1M sodium
bicarbonate buffer, pH 8.3. The wells were washed once

65

Standard curves were obtained for a monoclonal antibody,
12AB, and a rabbit polyclonal antibody, tittered against
human protein C which was obtained by immunoaffinity
chromatography over immobilized 7D7B10 antibody. The
milk Sample, taken from transgenic Mouse No. 5, contained
approximately 200 ng/ml protein C.
To assure proper protein C Structure as judged by immu
nocapture by two different monoclonal antibodies, as well as
by a polyclonal mixture of antibodies, the Samples for
Several different transgenic mice were Screened by ELISAS.
Table 2A shows essentially equivalent antigen levels, as

5,831,141
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judged by three different immunocaptures and detection by
ELISA. The majority of mice produced by microinjection of
WAPpC1 produced antigen levels in the 1-to-4-lig/ml range.

ture for 2 hours. Plates were washed 3 times in TET buffer.

The captured human protein C was activated by adding 120
All of Protac", a commercial reagent containing a Snake
venom enzyme (12 ml distilled water per vial), 30 ul TSP
buffer and 0.1% BSA, pH 7.5, per well. After incubation for

TABLE 2A

6-10 minutes at room temperature, 120 ul S-2366 (Kabi
substrate) at 25 mg/10.8 ml Tris pH 7.8 was added to each
well and the plates were incubated for 2-8 hours at room
temperature, or several days at 4 C. The amount of protein

hPC ANTIGEN ELISA (NG/ML)
MOUSE
ID-DAY

MONOCLONAL
LC-CAPTURE

MONOCLONAL
HC-CAPTURE

POLYCLONAL
CAPTURE

Y52-15
Y57-15

182O
930

353O
1150

41OO
288O

The concentration of human protein C in whey obtained
from transgenic mice, as well as milk, was also determined
in this manner, with equivalent results.
Similar assays were routinely carried out to assay protein
C in milk obtained from transgenic animals. Results
obtained using the 7D7B10 antibody in light-chain capture
ELISAS are compiled in Table 3, which Summarizes the
concentration of protein C in milk obtained from transgenic
mice during the first four lactation periods. Dashes indicate
that no test was done. All of the animals provided significant
levels of protein C in their milk. Preliminary results also
indicate that the Second lactation period is Sometimes Supe
rior to the other periods tested.

15

assays, 205 units (U) per mg, is similar to that of human
protein C of similar purity obtained from natural Sources. (A
“unit' is defined by pooling blood from many individuals
and determining activity in 1 ml of the pooled blood.)
TABLE 4
25

TABLE 3

hPC ELISA SCREENING (LIGHT CHAIN CAPTURE)
Day of Lactation
MOUSE ID

Y68-L2
Y51-L2
YS1-L3
Y52-L1
Y52-L2
Y57-L1
Y57-L2
RO3-L2
R12-L1
R12-L2

5-6

8-9

1.05
1.08
2.8O
0.55
1.52
1.47
1.90

2.88
O60
2.98

11-12

1.30
O.65

0.52
O.98
3.01
2.48

C activity in each Sample was determined by measuring
formation of the reaction product by absorption at 405 mm.
Results obtained using milk and whey from a transgenic
mouse and the pooled milk and whey of Several transgenic
mice appear in Table 4, which shows the amount and the
specific activity of protein C in the samples. Note that the
Samples were obtained either during the first lactation
period, L1, or were obtained from a Second and third
lactation, L2 and L3. The specific activity of the human
protein C obtained from transgenic mice determined in these

Protac TM-Specific Amidolytic Activity
Upon S-2366
U/ml

pig Ag/ml

U/mg

O34

2O6

Reconstituted Whey

O.O7

YS2-L1 Pool*:
YS2-L1 Milk Pool

O.23

1.12

Transgenic Whey Pool**
Transgenic Milk Pool**

1.12
O.43

0.55
2.10

205

*Pooled milk from days 5-15.
13-15

**L2 and L3 from mice Y51, Y52, Y57, RO3, R12.
35

O.56
1.79

0.95
1.35

40

240

45

Human protein C in the milk obtained from other species
can be measured by the same methods. Thus, protein C from
human plasma Spiked into pig milk was accurately detected
via the above-described ELISA.
EXAMPLE 7

50

Assay for Protein C Amidolytic Activity using the
Chromogenic Substrate S-2366

(1) Microtiter Well Assay

55

The enzymatic activity of protein C in the milk of
transgenic animals was measured directly using a chromoge
nic assay essentially as described by Odegaard et al., Hae

mostasis 17: 109 (1989). In this assay microtiter plate wells
were coated with the 7D7B10 monoclonal antibody (50
ug/ml) in 50 ul of 0.1M bicarbonate buffer, pH 8.6 at 4 C.
overnight. Plates were then rinsed with TET buffer (0.1M
Tris; 0.03M EDTA; 0.05% tween-20) and blocked with 400

til/well 1% BSA in PBS and incubated at room temperature
for 1 to 1.5 hours. After rinsing 3 times with TET buffer, 50
ul of whey sample and 50 ul of 0.1M Tris pH 7.5, 0.03M
EDTA was added per well and incubated at room tempera

60

(2) Amidolytic activity assay on nitrocellulose

Whey proteins were resolved by electrophoresis through
polyacrylamide gels under non-reducing conditions in the
presence of SDS. Following electrophoresis proteins were
transferred out of the gel and immobilized on a nitrocellu
lose membrane by electroblotting. SDS was removed from
the membrane by thorough washing in 0.05M Tris-Cl,
0.175M NaCl, .25% Triton X-100, pH 8.0, and the mem
brane was then equilibrated in 0.25M Tris-Cl pH 8.0.
Following equilibration the membrane was incubated in
Protac C, 0.25 U/ml in distilled water. A 1% agarose
indicator gel in 25 mM Tris-Cl pH 8 containing 1 mM
chromogenic Substrate S-2366 was then placed onto the gel,
and the filter and gel overlay were incubated under moist
conditions for 30–90 minutes at 37 C. Colored bands
generated by protein C activity on the filter were Visualized
under U.V. light, and photographed.
FIG. 8 shows the results obtained by this assay for milk
produced by transgenic mice that were Stably transformed
with a double stranded DNA comprising the 5' 4.2 kb WAP
promoter ligated via a linker to the 9.4 kb human genomic
protein C fragment. All of these transgenic mice produced
amidolytically active protein C in their milk, giving rise in
the blots to a strong band and a weak band of amidolytic
activity (FIG. 8, panel A). Notably, bands of the same
migration were detected in each whey Sample when a similar

blot was probed with an anti-protein C antibody (FIG. 8,
panel B).
EXAMPLE 8
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Determination of Protein C Produced in Transgenic
Mammals by Activated Partial Thromboplastin
Clotting Time ASSay
The activity of protein C was also measured in a clotting
time assay, the activated partial thromboplastin clotting time

5,831,141
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assay (APTT). In this assay, each well of a plastic Coag-a-

18

mate tray received 90 ul of PC-deficient plasma plus 10 ul
of an APC standard or unknown, diluted with Tris/saline/

BSA. The tray was then placed on an automated analyzer

(APTT mode, 240 second activation). The run was started,

which automatically performed the addition of 100 ul of
APTT reagent and 100 ul of 0.025M CaCl. Data obtained
using a Standard APC preparation was fitted to the equation
y-ax+b where y=clotting time and x=APC, which was then
used to determine the amount of APC in a sample.
The result of an APTT assay of whey pooled from
transgenic mice is shown in FIG. 4. The Standard curves in
the figure correlate the activity determined by the APTT
assay with the amount of active human protein C in mouse
milk or mouse whey. The activity in the APTT assay of the
whey Sample obtained from the transgenic mouse corre
sponded to a concentration of approximately 0.57 ug/ml,
interpolated from the Standard curve for human protein C in

5

(2) Immunoaffinity Chromatography
The resin immunosorbent (AffiprepTM) used to purify

human protein C in the whey of transgenic mice contained
3.3 mg 7D7B10 Mab/ml of Affiprep resin. The 7d7B10
Affiprep resin was assessed by mock immunopurification
using 30 tug of plasma derived hPC doped into control
15

Freshly concentrated whey (16 mg/ml, 930 mg total
protein, as determined by optical absorption at 280 nm) was

detected approximately 0.60 ug/ml of human protein C, as
protein. Thus, within the normal range of error of these
assays, human protein C produced in transgenic mice is as
active as the control human protein C.

Mapping of Calcium Dependent Conformer by
Metal-Dependent Immunoaffinity
Standard ELISAS were run in normal mouse milk whey
with varying concentrations of hPC or hPC without Gla
regions in the presence of 25 mM EDTA. After capture by
7D7B10, an assay replicating that effected with 25 mM
EDTA was treated with several washes of 25 mM CaCl, and
then was followed by the ELISA detection protocol
described previously. While de-Gla protein remained bound
to the capture antibody in the presence of CaCl2, the PC
Standard did not remain bound in the presence of added
CaCl2. It was observed that whey from the transgenic mouse
Y57 behaved in a similar manner to the y-carboxylated
native PC, Suggesting that it is also y-carboxylated like the

batch-loaded onto 13 ml of 7D7B10 Affiprep containing 3.3
mg 7D7B10 Mab/ml resin for 4 hours at 2 C., without
addition of carrier protein. The column was fresh and the

high total (background) protein loading was thought to be
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The column was then eluted with 25 mM CaCl in TBS
pH 7.2, followed by 100 mM CaCl in TBS, followed by 4M
NaCl, followed by 2M Na thiocyanate at 0.5 ml/min. The
column was re-equilibrated with 5 column volumes of 25
mM EDTA-TBS, 0.02% sodium azide.
35

then reconstituted to 50 mM imidazole, 0.1. NaCl buffer
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Purification of Human Protein C from the Milk of
45

50

mice. Assay of 100-fold concentrated 25 mM CaCl eluate
product from WAPpC1 transgenics showed 40% yield based
upon densitometry of SDS-PAGE stained with Coomassie
55

Blue (yield not determined for mock purification). The total

peak areas from mock- and WAPpC1 -whey were approxi
mately the same for all eluate peaks including the 2M Na
thiocyanate peak. Approximately 2 tug of hPC antigen

(ELISA with immunocapture using 7D7B10 Mab) was
60

pool was determined by ELISA using the 7D7B10 mono

clonal antibody (Mab). The combined pool contained

(14,000 MW cutoff) against 25 mM EDTA-TBS diluted

The area of the eluate peaks obtained from immunopuri
fication of whey from WAPpC1-transgenic mice was found
to be very Similar to the mock trial using an equivalent

amount of (plasma derived) hPC-doped whey from control

described above.

approximately 30 lighPC, determined by this assay, which
was within 20% of the total determined by adding determi
nations of the individual pools.
The combined pool, approximately 150 ml, was dialyzed

as per the method of Laemmli (1970), applied to a 15 well,
9 cmx2 cm, 4% stacking gel above a 7.5 cm, 7.5% resolving
(30%: 2.7% bis) sodium dodecylsulphate polyacrylamide
gel and electrophoresed (SDS-PAGE). After electrophoresis,
tion.

Milk from several WAPpC1 transgenic mouse lines was
pooled, chilled on ice, diluted 6-fold with 50 mM Tris-HCl,

Individual whey pools were thawed at 2 C.C, combined,
and the amount of human protein C (hPC) in the combined

Strength using nanopure water resulting in a 100-fold con
centration of protein.
Samples of these eluate pool concentrates were prepared

the gel was stained with 1.25% Coomassie Blue dye solu

(1) Preparation of Whey Samples

centrifugation, the whey was collected and pooled using a
pasteur pipet and pooled, being careful not to disturb the
fatty Overlayer or the casein pellet. Samples were removed
from the pool for later assay and then both the Samples and
the pooled whey were frozen and stored at -90° C. Human
protein C in Samples was determined by ELISA, as

All peak pools were dialyzed in a 100-fold dilution (by
nanopure water) of 50 mM imidazole, 0.1M NaCl buffer

using a 14,000 MW cutoff dialysis tubing, then lyophilized,

EXAMPLE 10

0.15M NaCl pH 7.2 (TBS) (1 ml milk per 5 ml TBS), and
centrifuged at 125,000xg for 30 minutes at 4 C. Following

enough to condition the column. The resin was then loaded
into a 1 cm diameter column and washed with 25 mM

EDTA-TBS until baseline optical density (O.D.) was
detected at 280 nm (3 column volumes to obtain <0.0005
O.D.)

native molecule.

Transgenic Animals

(nontransgenic) mouse whey. Approximately the same rela
tive amount of total protein was loaded onto the column (660
mg on a 10 mL Affiprep) and otherwise processed as
described below.

whey. An ELISA (not shown) of the same whey sample

EXAMPLE 9

5-fold with pure water. The dialyzed whey was concentrated
5-fold by lyophilization and Subsequent reconstitution with
nanopure water, to yield a final buffer concentration equiva
lent to 25 mM EDTA in TBS, and a 5-fold increase in protein
concentration. The concentrated whey contained 930 mg
protein, as estimated by optical absorption at 280 nm, at 16
mg/ml.

detected in the column fall through which had been com
bined with EDTA-TBS wash. Approximately 14 lug of hPC

was detected in the 25 mM Ca" eluate pool, less than 0.1
ug hPC antigen in the 100 mM Cat" eluate pool, no hPC
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antigen was detected in the 4M NaCl pool, approximately 10
lug of hPC was detected in the 2M Nathiocynate eluate pool.
Thus, 87% of the hPC antigen applied to the column was
accounted for in the total antigen recovered from column

5,831,141
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effluents. A 47% antigen yield was obtained based upon the

interaction is thought to be specific with the 7D7B10 Mab.
Overall, this two step procedure results in a minimum
purification factor of 27,000 for the hPC recovered from
mouse milk. A large-scale purification process could employ
a citrate or EDTA precipitation coupled with low Speed
centrifugation in place of the ultracentrifugation Step used

hPC antigen recovered in the 25 mM Cat" eluate peak.

The starting whey applied to the column, the 2M sodium

thiocyanate eluate, the 25 mM Cat eluate product, and a
reference hPC derived from plasma by the American Red

Cross (Lot #28300277, supplied by Dr. Carolyn Orthner)

for mouse milk.

were analyzed by SDS-PAGE, both reduced and non

Both amidolytic and anti-coagulant assays were per
formed upon immunopurified milk from transgenic mice.
Within the sensitivity of these assays, the amidolytic and
anti-coagulant activity was the same as plasma-derived
immunopurified protein C. For both types of assays, the
Specific activity was greater than 270 U/mg.

reduced. The 2M sodium thiocynate and 25 mM Caeluate

pools were concentrated as described above and 4 lug of
antigen applied to the gel for each lane. The immunopurified
hPC reference was applied to the gel as 4 ug total protein
based upon O.D. at 280 nm. Scanning densitometry of this
reference hPC indicated that the Sample was greater than
99% pure on nonreduced SDS-PAGE, and 71% pure on
reduced SDS-PAGE. Subsequent antigen assays performed

15

EXAMPLE 11

on the hPC reference material indicated the concentration of

the Sample to be Such that only 2.7 ug of the reference

Highly Efficient Expression of Active Protein C in
Transgenic Mammals using a Long Mouse Whey
Acid Protein Promoter Fragment and a Human
Genomic Protein C Fragment

sample was applied to the gel. The 25 mM Ca" eluate

product is greater than 94% pure based upon non-reduced
SDS-PAGE and 86% pure based upon reduced SDS-PAGE.

The staining intensity of the 25 mM Cat" eluate lanes is

consistent with our previous experience for 4 lug antigen
applications. The bands corresponding to reference hPC

possessed lighter intensity relative to the 25 mM Ca"
eluate. A slightly split band at approximately 62,000 relative

(A) DNA Constructs
25

molecular weight (Mr) is seen for both the non-reduced

reference hPC and the 25 mM Cat" eluate. A doublet at

about 40,000 Mr and a diffuse single band at 22,000 Mr is

seen for both the reduced reference hPC and 25 mM Cat"

eluate. The 22,000 Mr band appearing in the hPC reference
is seen to be Somewhat more diffuse or heterogeneous than

the similar band appearing in the 25 mM Ca" eluate from

(B) Production of Transgenic Animals

the whey of transgenic mice. The Sodium thiocyanate peak
showed a band in excess of 180,000 Mr in the nonreduced

sample and multiple bands at 50,000 Mr and 25,000 Mr in
the reduced Sample.
The chromatography of the WAPpC1-whey was nearly
identical to the mock run using plasma-derived hPC doped
into control whey. The total areas and yields of hPC in the
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25 mM Ca" eluates and areas of 2M sodium thiocyanate

peaks for both runs were Similar and thus the binding
characteristics of the 7D7B10 Mab onto transgenic hPC or
plasma-derived hPC were similar. This is consistent with the
Similarity found between plasma-derived and transgenic

45

hPC Ca"-dependent conformers as judged by ELISA

assays using the 7D7B10 Mab to immunocapture from
whey. The primary structure as judged by SDS-PAGE
appears to be similar, with the amount of C.-form and B-form
heavy chain being essentially the same for plasma-derived
and transgenic hPC; the transgenic having 68% C.-form and
32% ul-form while the plasma-derived material possessed
69% a-form and 31% B-form. The light chains were also
similar in size for both reference and transgenic hPC.
Previous experience with SDS-PAGE using Coomassie Blue
staining of hPC has shown linearity for both chains over the
range of 2-5 ugh PC applied to the gel. Thus, much of the
elements of post-translational, proteolytic processing
appears to have occurred properly in the mammary tissue.
The purity of these runs also demonstrates the Satisfactory
utility of the immunopurification procedure developed for
the murine system. It is believed that the tight binding of the
hPC antigen found by ELISA in the 2M thiocyanate peak of

the whey from transgenic mice (assay not done for mock
run) is typical of yields found for fresh immunosorbents and
not due to an aberrant hPC structure. The total background
protein did not seem to condition the column and thus the

The 5' 4.2 kb Sau3A-Kpn1 promoter fragment of the
mouse whey acidic protein promoter was cloned by Standard
techniques. The 9.4 kb genomic fragment of human protein
C beginning 21 basepairs upstream of the “A” in the protein
C start codon and ending at the Nhe site in the 3' end of the
protein C gene also was cloned by Standard techniques. The
4.2 kb promoter fragment and the 9.4 kb protein C fragment
were joined using a SalI linker, as shown in FIG. 6.
DNA was prepared and injected into mouse and pig
embryos as described hereinabove. Animals were tested for
integration of the DNA by PCR, also as described above.
Stable integration of the construct was detected in both mice
and pigs.

(C) Protein C in the Milk of Transgenic Mice.
The mice were reared to maturity, crossed and milk was
obtained from lactating females.
FIG. 7 depicts SDS-PAGE and western blot analysis of
whey from Six transgenic mice. AS shown in panel A,

transgenic mouse whey (lanes 1-6) and normal mouse whey
(lane 7) gave rise to Substantially the same Silver stain
pattern of bands after SDS-PAGE. As shown panel B, human
protein C readily was detected in the transgenic mice whey
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(lanes 1-6), but not in normal mouse whey (7), when the

Samples were blotted onto nitrocellulose, probed with an
anti-human protein C antibody, and Visualized by chemilu
minescence. The pattern of bands detected by the anti
human protein Cantibody in the transgenic mouse whey was
very similar to the pattern of bands detected in purified

55

human protein C (lane 8).

60

As shown in FIG. 8, protein C activity readily could be
detected in transgenic mouse whey. Panel B in the figure
shows the pattern of human protein C in mouse whey
samples resolved by SDS-PAGE under non-reducing con
ditions. Protein C was visualized by blotting onto
nitrocellulose, probing the filter with an anti-human protein
C antibody and detecting antibody binding by a Secondary
antibody-enzyme conjugate and the chromogenic Substrate
4-chloro-1-naphthol. Protein C reactive bands were substan
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tially the same in transgenic mice (lanes 3-8) and purified
human protein C (lane 1), and were absent from normal
mouse whey (lane 2).
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Amidolytic activity in the Samples is shown in Panel A.
An agarose gel Overlay containing chromogenic Substrate
revealed enzyme activity in whey from each transgenic
mouse (lanes 3-8) and in purified human protein C (lane 1),
but not in normal mouse whey (lane 2).
The amounts of human protein C produced by the trans
genic mice in their milk also was determined. Table 5 shows
the amounts of human protein C detected in the milk of Six
transgenic mice, as determined by 12A8 monoclonal ELISA
and by sheep anti-human protein C polyclonal ELISA. The
table also shows protein C amidolytic activity in whey from
the same samples. The ELISAS and the amidolytic activity
assay were performed as described hereinabove.
AS shown in the Table, protein C concentrations in the
transgenic mice by monoclonal ELISA ranged from approxi
mately 0.05 mg/ml to approximately 1.69 mg/ml. The con
centration of protein C in the milk of these mice was at least
40 fold more than the concentration of protein C observed in
other transgenic mice, Such as those noted in Table 2A, as Set
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TABLE 5

Detection of human protein C in the milk of
transgenic mice having the 5' 4.2 kb WAP-promoter
9.4 kb human genomic protein C construct stably
integrated in their genomes

MOUSE

NUMBER NUMBER
5.4
6.4
4.2.10
15 5.2.12
7.2.2
7.5.4

forth hereinabove.

Concentrations measured by polyclonal ELISA ranged
from 0.14 to 4 mg/ml, exceeding even more dramatically the
concentrations attained with the 2.4 kb 5’ WAP promoter, the
highest of which, as set forth in Table 2A, was 0.0041
mg/ml.
In addition, whey samples from the transgenic mice were
assayed for amidolytic activity and the results were com
pared with amidolytic activity of protein C in plasma.
Amidolytic activity in the samples is shown in Table 5,
expressed as the per cent of protein C activity in plasma. The
concentration of protein C in the whey Samples was adjusted
to equal the concentration in the normal plasma control.
The high concentration of protein C allowed the amidol
ytic activity to be assayed directly in whey. This contrasted
Sharply with the necessity to use a capture method to
concentrate protein C prior to amidolytic activity of whey
samples from mice transgenic for the 2.4 kb WAP promoter
fragment.
The amidolytic activity of protein C in the whey sample
was also compared with the activity of purified human
protein C diluted in whey. At comparable concentrations of
protein C, amidolytic activity in transgenic mouse whey was
nearly the same as that of human protein C.

PC
PC ANTIGEN
TRANS- ANTIGEN
BY POLY.
GENE
BY 12A8CLONAL
COPY MABELISA
ELISA
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14
1O
1O
2O
2
3O

(mg/ml)

(mg/ml)

0.05 + -0.01
1.00 + -0.03
1.69 - -0.09
0.96+ -0.09
0.33 + -0.03
O.96 - -0.04

0.14 +
2.94 +
3.98 2.50 +
0.89 +
1.99 -

-0.01
-0.09
-0.09
-0.10
-0.14
-0.33

AMIDOLYTIC
ACTIVITY
IN WHEY

(%.N-PLASMA)
N.D.
56.2
54.8
54.9
N.D.
18.8

Finally, Some of the transgenic mice were Sacrificed and
examined to determine the tissue specificity of expression of
human protein C. RNAblots and immuno in situ histological
examination showed that at least 99% of the protein C
expression occurred in the mammary glands in these ani
mals. These results contrast with the results achieved using
whey acidic protein promoter constructs that contained only
the 2.4 kb promoter fragment. Constructs using this pro
moter to drive protein expression in transgenic mice engen
dered expression that differed from the normal pattern of
whey acidic protein expression during development and in
adult tissues. In fact, this was true for the whey acidic
protein itself. Thus, in addition to providing high levels of
expression of a protein, the 4.2 kb 5’ WAP promoter frag
ment also provides greater tissue specificity of expression in
the adult mouse.

35

40

(D) Purification of Protein C from Transgenic Mouse

Whey
Human protein C was partially purified from transgenic
mouse whey by immunoaffinity chromatography using the
12A8 monoclonal antibody immobilized on a Sepharose
support. Bound protein C was eluted in 0.1M glycine, 0.02M
histidine, 0.15M NaCl pH 10. Transgenic protein C purified
in this manner revealed essentially the same banding pattern
upon SDS-AAGE as a standard preparation of purified
human protein C.

SEQUENCE LISTING

( 1) GENERAL INFORMATION:
( i i i ) NUMBER OF SEQUENCES: 1
( 2) INFORMATION FOR SEQ ID NO:1:
( i) SEQUENCE CHARACTERISTICS:
( A ) LENGTH: 69 base pairs
(B) TYPE: nucleic acid
( C ) STRANDEDNESS: single
(D) TOPOLOGY: linear
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:1:
G G T AC GT C G A
T C G T G GC CA

CA CAG G T G C C

AGTG C C T C CA

GAA T G T G G CA

G CT CACA A G C

C T C C T G CT GT

6 O
69
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What we claim is:

1. A transgenic non-human mammal containing a DNA
Sequence Stably integrated in its genome, wherein Said
exogenous DNA sequence comprises the 5' 4.2 kb Sau3A
Kpn1 promoter of the mouse whey acidic protein gene,
operably linked to a DNA sequence encoding heterologous
protein C and a Signal peptide, wherein Said whey acidic
protein promoter is specifically active in mammary cells and
Said Signal peptide is effective in directing the Secretion of
Said protein C into the milk of Said transgenic mammal,
wherein the activated form of Said Secreted protein C has an
enzymatic activity of at least 50% as plasma-derived protein
C, and wherein Said transgenic mammal is Selected from the
group consisting of mice, rats, rabbits, pigs, sheep,goats and
COWS.

2. The transgenic non-human mammal of claim 1,
wherein Said protein C is human protein C, and wherein Said
DNA sequence encoding protein C further comprises regu
latory elements located in the non-coding regions of the
human protein C gene, wherein Said regulatory elements are
the AUG start codon, donor and acceptor Splice Signals, the
Secretion peptide, translation termination Signal, transcrip
tion termination signal, and polvadenylation signal.
3. The transgenic non-human mammal of claim 1,
wherein Said DNA sequence encoding human protein C
comprises the human protein C gene from 21 basepairs
upstream of the protein C start condon to the NehI site in the
3' end of the protein C gene.
4. The transgenic non-human mammal of claim 1,
wherein Said exogenous DNA sequence comprises a DNA
Sequence comprising the 5' 4.2 kb Sau3A-Kpn1 promoter
fragment of the mouse whey acidic protein promoter ligated
directly or by a linker to a fragment of the human protein C
gene beginning 21 basepairs upstream of the protein C Start
codon and ending at the Nhe site in the 3' end of the protein
C gene.
5. A process for the production of heterologous protein C,
comprising the Steps of:
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(A) providing a non-human transgenic mammal whose

genome comprises a stably integrated DNA sequence
comprising the 5' 4.2 kb Sau3A-Kpn1 promoter of the
mouse whey acidic protein gene, operably linked to a
DNA sequence encoding a heterologous protein C and
a signal peptide, Said promoter being Specifically active
in mammary cells and Said Signal peptide being effec
tive in directing the Secretion of Said protein C into the
milk of Said transgenic mammal, and wherein Said
transgenic mammal is Selected from the group consist
ing of mice, rats, rabbits, pigs, sheep, goats and cows;
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into the milk of Said mammal.
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(B) producing milk from Said transgenic mammal,
wherein Said milk contains Said Secreted protein C, and
wherein the activated form of Said protein C has an
enzymatic activity of at least 50% as plasma-derived
protein C,

(C) collecting said milk, and
(D) isolating said protein C from Said milk.

6. The process of claim 5, wherein said protein C is
human protein C, and wherein Said DNA sequence encoding
protein C further comprises regulatory elements located in
the non-coding regions of the human protein C gene,
wherein Said regulatory elements are the AUG Start codon,
donor and acceptor Splice Signals, the Secretion peptide,
translation termination Signal, transcription termination
Signal, and polyadenylation signal.
7. The process of claim 5, wherein said DNA sequence
encoding human protein C comprises the human protein C
gene from 21 basepairs upstream of the protein C Start codon
to the Nhe site in the 3' end of the protein C gene.
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8. The process of claim 5, wherein said DNA comprises
a DNA sequence comprising the 5' 4.2 kb Sau3A-Kpn1
promoter fragment of the mouse whey acidic protein pro
moter ligated directly or by a linker to a fragment of the
human protein C gene beginning 21 basepairs upstream of
the protein C start codon and ending at the Nhe site in the
3' end of the protein C gene.
9. A process for producing non-human transgenic
mammals, comprising the steps of (A) providing a mixture
containing a double-stranded DNA; (B) Subjecting said
mixture to anion-exchange high performance liquid chro
matography to obtain purified double-stranded DNA; and
thereafter (C) microinjecting an aqueous buffer Solution
containing Said purified double-Stranded DNA into an ani
mal embryo, wherein said double-stranded DNA is selected
from the group consisting of a double-Stranded DNA com
prising the 5' 4.2 kb Sau3A-Kpn1 promoter fragment of the
mouse whey acidic protein promoter, a double-Stranded
DNA comprising a fragment of the human protein C gene
beginning 21 basepairs upstream of the protein C Start codon
and ending at the Nhe site in the 3' end of the protein C
gene, and a double-Stranded DNA comprising a DNA
Sequence comprising the 5' 4.2 kb Sau3A-Kpn1 promoter
fragment of the mouse whey acidic protein promoter ligated
directly or by a linker to a fragment of the human protein C
gene beginning 21 basepairs upstream of the protein C Start
codon and ending at the Nhe site in the 3' end of the protein
C gene, wherein the activated form of protein C encoded by
said double-stranded DNA has an enzymatic activity of at
least 50% as plasma-derived protein C, and wherein said
transgenic mammal is Selected from the group consisting of
mice, rats, rabbits, pigs, sheep, goats and cows.
10. A transgenic non-human mammal containing a DNA
Sequence Stably integrated in its genome, wherein Said DNA
Sequence comprises the 5' 4.2 kb Sau3A-Kpn1 promoter
fragment of the mouse whey acidic protein promoter, oper
ably linked to a DNA sequence encoding a heterologous
polypeptide whereby Said polypeptide is expressed Specifi
cally in mammary cells of Said transgenic mammal and Said
polypeptide comprises a signal peptide, Said Signal peptide
being effective in directing the Secretion of Said polypeptide
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11. The transgenic non-human mammal of claim 10,
wherein Said transgenic non-human mammal is Selected
from the group consisting of mice, rats, rabbits, pigs, sheep,
goats and cows.
12. The mammal of claim 11, wherein Said transgenic
non-human mammal is sheep.
13. The mammal of claim 11, wherein said transgenic
non-human mammal is a goat.
14. The mammal of claim 11, wherein Said transgenic
non-human mammal is a cow.
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15. A process for the production of a heterologous
polypeptide in the milk of a transgenic non-human mammal,
comprising the Steps of:

(A) providing a non-human transgenic mammal whose
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genome comprises a stably integrated DNA sequence
comprising the 5' 4.2 kb Sau3A-Kpn1 promoter of the
mouse whey acidic protein gene, operably linked to a
DNA sequence encoding a heterologous polypeptide
and a signal peptide, Said promoter being Specifically
active in mammary cells and Said Signal peptide being
effective in directing the Secretion of Said polypeptide
into the milk of Said transgenic mammal;
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(B) producing milk from said transgenic mammal,
wherein Said milk contains Said polypeptide;

(C) collecting said milk, and

5,831,141
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(D) isolating said polypeptide from Said milk.
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19. The process of claim 16, wherein said transgenic
16. The process of claim 15, wherein said transgenic non-human mammal is a cow.
non-human mammal is Selected from the group consisting of
20. An isolated DNA molecule which regulates the
expression of a heterologous gene, wherein Said DNA mol
mice, rats, rabbits, pigs, sheep,goats and cows.
17. The process of claim 16, wherein said transgenic 5 ecule consists of the 5' 4.2 kb Sau3A-Kpn1 promoter of the
mouse whey acidic protein gene.
non-human mammal is a sheep.
18. The process of claim 16, wherein said transgenic
k
k
k
k
k
non-human mammal is a goat.
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